Fig. 4From: Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancerEffect of short-term treatment with BGJ398 on pERK and ERBB family receptors. A SW780 and (B) RT4 parental cells were treated with BGJ398 for 4–72 h and changes in pERK and ERBB family receptors was determined by western blot. Data shown are from a representative experimentBack to article page